Eculizumab News and Research

RSS
FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

New treatment for adults with rare, life-threatening blood disease receives FDA approval

New treatment for adults with rare, life-threatening blood disease receives FDA approval

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Scientists propose potential new treatment for Gaucher disease

Scientists propose potential new treatment for Gaucher disease

Eculizumab drug provides new hope for kidney failure patients

Eculizumab drug provides new hope for kidney failure patients

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

UAB researcher awarded NIH grant to study pathogenesis of thrombotic microangiopathy

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Cincinnati Children’s, Alexion Pharmaceuticals establish ‘Rare Disease Innovation Fund’

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Penn research team discovers new cost-effective way to fight rare blood disorder

Penn research team discovers new cost-effective way to fight rare blood disorder

Penn researchers identify possible new way to fight rare blood disorder

Penn researchers identify possible new way to fight rare blood disorder

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients